scholarly journals Seroconversion after Recombinant Hepatitis B Vaccination

1970 ◽  
Vol 11 (2) ◽  
pp. 143-150 ◽  
Author(s):  
Abhijit Guho ◽  
Md Abdul Ahad ◽  
Md Abdus Salam ◽  
Md Abdul Alim ◽  
AKM Enamul Haque ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Virus Infection ◽  
Recombinant Hepatitis ◽  
Protective Level ◽  
Significant Difference ◽  
B Virus ◽  
Study Population

Background: Hepatitis B virus infection is an important public health problem with significant morbidity andmortality. Recombinant hepatitis B vaccine for the prevention of hepatitis B virus infection is in practice in differentparts of the world since its availability in 1986. Government of Bangladesh has also included hepatitis B vaccine inEPI schedule since 2005.Materials and methods: This study was carried out to assess the seroconversion status among hepatitis Bvaccinated individuals. A total of 190 individuals including 150 vaccinated persons and 40 non-vaccinated apparentlyhealthy individuals were included as study population. Sources of vaccinated persons were from both EPI and non-EPI schedule of vaccination. Age and sex matched non-vaccinated individuals served as controls for the study. Allindividuals constituting the study population were screened for HBsAg by Immunochromatographic strip test andonly HBsAg-negative persons were included for estimation of their anti-HBs titer.Results: Out of 150 vaccinated individuals, 133(88.67%) were found to have anti-HBs titer in the protective level(>10 IU/L), while 17(11.33%) individuals had anti-HBs titer below the protective level (<10 IU/L). All non-vaccinatedcontrols had anti-HBs titers below the protective level. Regarding immune response developed among vaccinatedindividuals, 67.78%, 23.33% and 8.89% were good-responders, hypo-responders and non-responders respectively.Mean titer of anti-HBs was found significantly higher among recipients who received booster dose than those whoreceived 3 doses schedule (863.39 IU/L vs. 262.40 IU/L), indicating high antibody titer develops after booster dose.Vaccinated group included 85 (56.67%) men and 65 (43.33%) women with protective level of anti-HBs titer foundin 85.88% male and 92.31% female individuals. There was no significant difference of anti-HBs titer between maleand female (p>0.05). Vaccinated individuals from lower socioeconomic condition have had comparatively low rateof protective antibody than people from middle and upper classes.Conclusion: Recombinant HB vaccine induces good level of protective immunity among vaccinated persons.Keywords: Hepatitis B; hepatitis B vaccine; seroconversion; BangladeshDOI: 10.3329/jom.v11i2.5461J MEDICINE 2010; 11 : 143-150

scholarly journals Role of Booster Dose on Antibody Titer after Recombinant Hepatitis B Vaccination

1970 ◽  
Vol 10 (2) ◽  
pp. 67-76 ◽  
Author(s):  
Md Abdul Ahad ◽  
Md Abdul Alim ◽  
Abhijit Guho ◽  
Quazi Tarikul Islam ◽  
Khan Abul Kalam Azad
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Booster Dose ◽  
Hepatitis B Vaccination ◽  
Hepatitis B Virus Infection ◽  
Recombinant Hepatitis ◽  
Protective Level ◽  
B Virus ◽  
Study Population

Hepatitis B virus infection is an important public health problem with significant morbidity and mortality. Recombinant hepatitis B vaccination for the prevention of hepatitis B virus infection is in practice in different parts of the world since its availability in 1986. Government of Bangladesh has also included hepatitis B vaccine in EPI schedule since 2005. This study was carried out to assess the seroconversion status among hepatitis B vaccinated individuals. A total of 190 individuals including 150 vaccinated persons and 40 non-vaccinated apparently healthy individuals were included as study population. Sources of vaccinated persons were from both EPI and non-EPI schedule of vaccination. Age and sex matched non-vaccinated individuals served as controls for the study. All individuals constituting the study population were screened for HBsAg by Immunochromatographic strip test and only HBsAg-negative persons were included for estimation of their anti-HBs titer. Out of 150 vaccinated individuals, 133(88.67%) were found to have anti-HBs titer in the protective level (e"10 IU/L), while 17(11.33%) individuals had anti-HBs titer below the protective level (<10 IU/L). All non-vaccinated controls had anti- HBs titers below the protective level. Immune response developed among vaccinated individuals, 67.78%, 23.33% and 8.89% were good-responders, hypo-responders and non-responders respectively. Mean titer of anti-HBs was found significantly higher among recipients who received booster dose than those who received 3 doses schedule (863.39 IU/L vs. 262.40 IU/L), indicating high antibody titer develops after booster dose. Vaccinated group included 85 (56.67%) men and 65 (43.33%) women with protective level of anti-HBs titer found in 85.88% male and 92.31% female individuals.   doi: 10.3329/jom.v10i2.2817 J MEDICINE 2009; 10 : 67-76

Persistence of Protection Against Hepatitis B Virus Infection Among Adolescents Vaccinated With Recombinant Hepatitis B Vaccine Beginning at Birth

2008 ◽  
Vol 27 (10) ◽  
pp. 881-885 ◽  
Author(s):  
Stephanie R. Bialek ◽  
William A. Bower ◽  
Ryan Novak ◽  
Louisa Helgenberger ◽  
Steven B. Auerbach ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Virus Infection ◽  
Recombinant Hepatitis ◽  
B Virus

scholarly journals Is There any Difference in Antibody Titer Between Children and Adults after Recombinant Hepatitis B Vaccination?

1970 ◽  
Vol 21 (1) ◽  
pp. 1-11
Author(s):  
M Abdul Ahad ◽  
M Abdul Alim ◽  
Abhiji Guho ◽  
ARM Saifuddin Ekram
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antibody Titer ◽  
Booster Dose ◽  
Hepatitis B Vaccination ◽  
Hepatitis B Virus Infection ◽  
Recombinant Hepatitis ◽  
Protective Level ◽  
B Virus ◽  
Study Population

Hepatitis B virus infection is an important public health problem with significant morbidity and mortality. Recombinant hepatitis B vaccine for the prevention of hepatitis B virus infection is in practice in different parts of the world since its availability in 1986. Government of Bangladesh has also included hepatitis B vaccine in EPI schedule since 2005. This study was carried out to assess the seroconversion status among hepatitis B vaccinated individuals. A total of 190 individuals including 150 vaccinated persons and 40 non-vaccinated apparently healthy individuals were included as study population. Sources of vaccinated persons were from both EPI and non-EPI schedule of vaccination. Age and sex matched non-vaccinated individuals served as controls for the study. All individuals constituting the study population were screened for HBsAg by Immunochromatographic strip test and only HBsAg-negative persons were included for estimation of their anti-HBs titer. Out of 150 vaccinated individuals, 133(88.67%) were found to have anti-HBs titer in the protective level (≥10 IU/L), while 17(11.33%) individuals had anti-HBs titer below the protective level (<10 IU/L). All non-vaccinated controls had anti-HBs titers below the protective level. Regarding immune response developed among vaccinated individuals, 67.78%, 23.33% and 8.89% were good-responders, hypo-responders and nonresponders respectively. Mean titer of anti-HBs was found significantly higher among recipients who received booster dose than those who received 3 doses schedule (863.39 IU/L vs. 262.40 IU/L), indicating high antibody titer develops after booster dose. Vaccinated group included 85 (56.67%) men and 65 (43.33%) women with protective level of anti-HBs titer found in 85.88% male and 92.31% female individuals. Vaccinated individuals from lower socioeconomic condition have had comparatively low rate of protective antibody than people from middle and upper classes. Recombinant HB vaccine induces good level of protective immunity among vaccinated persons. The present study showed that the proportion of adults (93.33%) developed level of protective antibody titer was higher than that of children (83.33%). It indicates that there is difference of antibody titer between children and adults after recombinant Hepatitis B vaccination.    doi: 10.3329/taj.v21i1.3210 TAJ 2008; 21(1): 1-11

The efficacy of accelerated, multiple, double-dose hepatitis B vaccine against hepatitis B virus infection in cancer patients receiving chemotherapy

2015 ◽  
Vol 34 (5) ◽  
pp. 372-379 ◽  
Author(s):  
Jaswinder Singh Sodhi ◽  
Wasim Raja ◽  
Showkat Ali Zargar ◽  
Abid Showkat ◽  
Shaheena Parveen ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Cancer Patients ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Virus Infection ◽  
Double Dose ◽  
B Virus

Hepatitis B vaccine in the prevention of perinatally transmitted hepatitis B virus infection: Final report on a West Midlands pilot study

1990 ◽  
Vol 30 (2) ◽  
pp. 113-116 ◽  
Author(s):  
Susan M. Wheeley ◽  
Elizabeth H. Boxall ◽  
Michael J. Tarlow ◽  
A. Rashid Gatrad ◽  
Janet Anderson ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Pilot Study ◽  
Virus Infection ◽  
Hepatitis B ◽  
Hepatitis B Vaccine ◽  
Final Report ◽  
Hepatitis B Virus Infection ◽  
B Virus ◽  
West Midlands

HEPATITIS B VACCINE: A DIAGNOSTIC TEST FOR PREVIOUS HEPATITIS B VIRUS INFECTION?

The Lancet ◽  
1984 ◽  
Vol 323 (8382) ◽  
pp. 916-917 ◽  
Author(s):  
J.C. Chaput ◽  
A. Poitrine ◽  
S. Naveau ◽  
T. Poynard ◽  
J. Pillot
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Diagnostic Test ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Virus Infection ◽  
B Virus
Sign in / Sign up

Export Citation Format

Share Document